- Home
- ATER vs CANF Comparison
ATER vs CANF Comparison
Compare ATER & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATER | CANF |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 6.1M |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ATER | CANF |
|---|---|---|
| Price | $0.56 | $4.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | ★ 62.9K | 24.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,045,000.00 | N/A |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | $7.48 | $290,391.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.17 |
| 52 Week High | $3.50 | $4.85 |
Technical Indicators
Market Signals| Indicator | ATER | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 36.62 | 62.70 |
| Support Level | $0.52 | $3.93 |
| Resistance Level | $0.92 | $4.74 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 21.38 | 69.32 |
Price Performance
Historical ComparisonAbout ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.